INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $457,298 | +45629.8% | 8,779 | +46105.3% | 0.00% | – |
| Q2 2022 | $1,000 | -92.3% | 19 | -96.4% | 0.00% | – |
| Q3 2020 | $13,000 | -99.3% | 526 | -99.2% | 0.00% | -100.0% |
| Q2 2020 | $1,755,000 | +162.7% | 68,359 | +57.3% | 0.00% | +100.0% |
| Q1 2020 | $668,000 | +1.1% | 43,453 | +125.7% | 0.00% | +100.0% |
| Q4 2019 | $661,000 | +66000.0% | 19,256 | +71218.5% | 0.00% | – |
| Q2 2018 | $1,000 | -99.9% | 27 | -100.0% | 0.00% | -100.0% |
| Q1 2018 | $1,889,000 | -16.7% | 89,743 | -42.7% | 0.01% | -16.7% |
| Q4 2017 | $2,267,000 | -7.7% | 156,585 | +0.6% | 0.01% | -14.3% |
| Q3 2017 | $2,456,000 | +8.1% | 155,619 | -15.0% | 0.01% | 0.0% |
| Q2 2017 | $2,273,000 | +63.1% | 183,035 | +113.3% | 0.01% | +75.0% |
| Q1 2017 | $1,394,000 | – | 85,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |